Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region; Asia Diabetes Foundation, Shatin, Hong Kong Special Administrative Region.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region; Asia Diabetes Foundation, Shatin, Hong Kong Special Administrative Region.
Diabetes Res Clin Pract. 2023 Sep;203:110855. doi: 10.1016/j.diabres.2023.110855. Epub 2023 Jul 28.
To describe health-related quality of life (HRQoL) and identify associated factors in patients with type 2 diabetes mellitus (T2DM) treated with oral glucose-lowering drugs (OGLDs).
This retrospective, cross-sectional analysis included adults with T2DM from 11 Asian countries/regions prospectively enrolled in the Joint Asian Diabetes Evaluation (JADE) Register (2007-2019) with available EuroQol-5D (EQ-5D-3L) data.
Of 47,895 included patients, 42,813 were treated with OGLDs + lifestyle modifications (LSM) and 5,082 with LSM only. Among those treated with OGLDs, 60% received sulphonylureas (SUs), of whom 47% received gliclazide. The OGLD + LSM group had a lower mean EQ-5D-3L index score than the LSM-only group (p < 0.001). The most affected EQ-5D-3L dimensions in OGLD + LSM-treated patients were pain/discomfort (26.2%) and anxiety/depression (22.6%). On multivariate analysis, good HRQoL was positively associated with male sex, education level, balanced diet and regular exercise, and negatively with complications/comorbidities, self-reported hypoglycaemia, smoking, HbA1c, age, body mass index and disease duration. Patients receiving gliclazide vs non-gliclazide SUs had lower HbA1c and better HRQoL in all dimensions (p < 0.001).
Demographic, physical and psychosocial-behavioural factors were associated with HRQoL in patients with T2DM. Our real-world data add to previous evidence that gliclazide is an effective OGLD, with most treated patients reporting good HRQoL. A plain language summary of this manuscript is available here.
描述 2 型糖尿病（T2DM）患者使用口服降糖药物（OGLD）治疗后的健康相关生活质量（HRQoL），并确定相关影响因素。
本回顾性、横断面分析纳入了来自 11 个亚洲国家/地区的 T2DM 成年患者，这些患者前瞻性地参加了联合亚洲糖尿病评估（JADE）登记研究（2007-2019 年），且均具有欧洲五维健康量表（EQ-5D-3L）数据。
在纳入的 47895 例患者中，42813 例接受 OGLD+生活方式改变（LSM）治疗，5082 例仅接受 LSM 治疗。在接受 OGLD 治疗的患者中，60%接受磺酰脲类药物（SUs）治疗，其中 47%接受格列齐特治疗。与仅接受 LSM 治疗的患者相比，OGLD+LSM 治疗组的平均 EQ-5D-3L 指数评分更低（p<0.001）。在 OGLD+LSM 治疗的患者中，受影响最严重的 EQ-5D-3L 维度是疼痛/不适（26.2%）和焦虑/抑郁（22.6%）。多变量分析显示，良好的 HRQoL 与男性、教育程度、均衡饮食和规律运动呈正相关，与并发症/合并症、自述低血糖、吸烟、糖化血红蛋白（HbA1c）、年龄、体重指数和疾病持续时间呈负相关。与非格列齐特 SUs 相比，接受格列齐特治疗的患者在所有维度的 HbA1c 更低，HRQoL 更好（p<0.001）。
人口统计学、身体和心理社会行为因素与 T2DM 患者的 HRQoL 相关。我们的真实世界数据增加了之前的证据，即格列齐特是一种有效的 OGLD，大多数接受治疗的患者报告 HRQoL 良好。本文的通俗语言摘要可在此处查看。
